{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:02:05Z","timestamp":1780718525313,"version":"3.54.1"},"reference-count":44,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.2169\/internalmedicine.6280-25","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T22:08:39Z","timestamp":1760566119000},"page":"1450-1457","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt"],"prefix":"10.2169","volume":"65","author":[{"given":"Shigeo","family":"Shimose","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"},{"name":"Department of Medicine, Iwamoto Internal Medicine Clinic, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Niizeki","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotake","family":"Shirono","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Huang DQ, Singal AG, Kanwal F, et al. Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology. Nat Rev Gastroenterol Hepatol 20: 797-809, 2023.","DOI":"10.1038\/s41575-023-00818-8"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391: 1163-1173, 2018.","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shimose S, Hiraoka A, Casadei-Gardini A, et al. The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma. Hepatol Res 53: 104-115, 2023.","DOI":"10.1111\/hepr.13843"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Finn RS, Qin S, Piscaglia F, et al. Characterization of tumor responses in patients with unresectable hepatocellular carcinoma treated with lenvatinib in the phase 3 randomized trial: REFLECT. Liver Cancer 13: 537-547, 2024.","DOI":"10.1159\/000537947"},{"key":"5","unstructured":"5. Hiraoka A, Kumada T, Hatanaka T, et al. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatol Res 51: 880-889, 2021."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yamashita T, Kudo M, Ikeda K, et al. REFLECT - a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 55: 113-122, 2020.","DOI":"10.1007\/s00535-019-01642-1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hasegawa K, Takemura N, Yamashita T, et al.; committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res 53: 383-390, 2023.","DOI":"10.1111\/hepr.13892"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Shimose S, Koya S, Kawaguchi T, et al. Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma. Clin Mol Hepatol 27: 616-619, 2021.","DOI":"10.3350\/cmh.2021.0258"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Narita R, Kotoh K, Yoneda A, Motomura M, Harada M. Factors raising serum ammonia level during lenvatinib treatment of patients with hepatocellular carcinoma. Anticancer Res 40: 5271-5276, 2020.","DOI":"10.21873\/anticanres.14531"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hidaka H, Uojima H, Nakazawa T, et al. Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: a prospective cohort study. Hepatol Res 50: 1083-1090, 2020.","DOI":"10.1111\/hepr.13531"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ohya K, Kawaoka T, Namba M, et al. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. Sci Rep 9: 12101, 2019.","DOI":"10.1038\/s41598-019-48045-z"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kirino S, Tsuchiya K, Kurosaki M, et al. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS One 15: e0231828, 2020.","DOI":"10.1371\/journal.pone.0231828"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Fujiwara K, Kondo T, Fujimoto K, et al. Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma. J Gastroenterol 59: 515-525, 2024.","DOI":"10.1007\/s00535-024-02097-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yokoyama K, Fukuda H, Yamauchi R, et al. Long-term effects of rifaximin on patients with hepatic encephalopathy: its possible effects on the improvement in the blood ammonia concentration levels, hepatic spare ability and refractory ascites. Medicina (Kaunas) 58: 1276, 2022.","DOI":"10.3390\/medicina58091276"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hayakawa Y, Tamaki N, Nakanishi H, et al. Add-on therapeutic effects of rifaximin on treatment-resistant hepatic encephalopathy. Intern Med 62: 973-978, 2023.","DOI":"10.2169\/internalmedicine.0212-22"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nakai M, Suda G, Ogawa K, et al. Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients. PLoS One 17: e0270786, 2022.","DOI":"10.1371\/journal.pone.0270786"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kawaratani H, Kondo Y, Tatsumi R, et al. Long-term efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: a multicenter retrospective study. J Clin Med 11: 2022.","DOI":"10.3390\/jcm11061571"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Suzuki H, Sezaki H, Suzuki F, et al. Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy. Hepatol Res 49: 1406-1413, 2019.","DOI":"10.1111\/hepr.13415"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362: 1071-1081, 2010.","DOI":"10.1056\/NEJMoa0907893"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kawaguchi T, Suzuki F, Imamura M, et al. Rifaximin-altered gut microbiota components associated with liver\/neuropsychological functions in patients with hepatic encephalopathy: an exploratory data analysis of phase II\/III clinical trials. Hepatol Res 49: 404-418, 2019.","DOI":"10.1111\/hepr.13300"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Suzuki K, Endo R, Takikawa Y, et al. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: a phase II\/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. Hepatol Res 48: 411-423, 2018.","DOI":"10.1111\/hepr.13045"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kaji K, Saikawa S, Takaya H, et al. Rifaximin alleviates endotoxemia with decreased serum levels of soluble CD163 and mannose receptor and partial modification of gut microbiota in cirrhotic patients. Antibiotics (Basel) 9: 145, 2020.","DOI":"10.3390\/antibiotics9040145"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 56: 593-619, 2021.","DOI":"10.1007\/s00535-021-01788-x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tateishi R, Matsumura T, Okanoue T, et al.; LUCID study investigators. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol 56: 261-273, 2021.","DOI":"10.1007\/s00535-020-01754-z"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Zacharias HD, Kamel F, Tan J, Kimer N, Gluud LL, Morgan MY. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev 7: CD011585, 2023.","DOI":"10.1002\/14651858.CD011585.pub2"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Elmoursi A, Abdelsattar AT, Khalil F, et al. Efficacy and safety of rifaximin in the prevention of recurrent episodes of hepatic encephalopathy: a systematic review and meta-analysis. Turk J Gastroenterol 34: 584-592, 2023.","DOI":"10.5152\/tjg.2023.22575"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Hiraoka A, Kumada T, Kudo M, et al.; Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer 6: 204-215, 2017.","DOI":"10.1159\/000452846"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76: 681-693, 2022.","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ogushi K, Chuma M, Uojima H, et al. Safety and efficacy of lenvatinib treatment in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice: a multicenter analysis. Clin Exp Gastroenterol 13: 385-396, 2020.","DOI":"10.2147\/CEG.S256691"},{"key":"30","unstructured":"30. Simon-Talero M, Roccarina D, Martinez J, et al.; Baveno VI-SPSS group from the Baveno Cooperation. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology 154: 1694-1705. e4, 2018."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 33: 739-747, 2011.","DOI":"10.1111\/j.1365-2036.2011.04590.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Nakane T, Fukunaga S, Nakano D, et al. Impact of metabolic dysfunction-associated fatty liver disease on the incidence of <i>Helicobacter pylori<\/i>-negative gastric cancer. Hepatol Res 54: 540-550, 2024.","DOI":"10.1111\/hepr.14010"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Chen B, Zhang L, Cheng J, et al. Risk factors for hepatic encephalopathy in hepatocellular carcinoma after sorafenib or lenvatinib treatment: a real-world study. Drug Des Devel Ther 16: 4429-4437, 2022.","DOI":"10.2147\/DDDT.S386829"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Kuwahara A, Sasaki R, Fukushima M, et al. Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia. JGH Open 4: 775-776, 2020.","DOI":"10.1002\/jgh3.12351"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Namba M, Kawaoka T, Aikata H, et al. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. Clin J Gastroenterol 12: 341-346, 2019.","DOI":"10.1007\/s12328-019-00938-2"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Tilg H, Adolph TE, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab 34: 1700-1718, 2022.","DOI":"10.1016\/j.cmet.2022.09.017"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Barreto CMA, do Valle EA, Moreira JPL, et al. Gut-related molecules as potential biomarkers in patients with decompensated cirrhosis. Ann Hepatol 30: 101567, 2024.","DOI":"10.1016\/j.aohep.2024.101567"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Fujimoto Y, Namisaki T, Takeda S, et al. Leaky gut and severe adverse events in advanced hepatocellular carcinoma treated with lenvatinib. Anticancer Res 42: 4895-4905, 2022.","DOI":"10.21873\/anticanres.15995"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39. Xu D, Gao J, Gillilland M 3rd, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 146: 484-496. e4, 2014.","DOI":"10.1053\/j.gastro.2013.10.026"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Enomoto M, Kaji K, Nishimura N, et al. Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. Dig Liver Dis 54: 1392-1402, 2022.","DOI":"10.1016\/j.dld.2022.04.012"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Fujimoto Y, Kaji K, Nishimura N, et al. Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity. World J Gastroenterol 27: 8323-8342, 2021.","DOI":"10.3748\/wjg.v27.i48.8323"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Kawaguchi T, Torimura T. Leaky gut-derived tumor necrosis factor-\u03b1 causes sarcopenia in patients with liver cirrhosis. Clin Mol Hepatol 28: 177-180, 2022.","DOI":"10.3350\/cmh.2021.0246"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Kimura M, Go M, Yamada S, Asano H, Usami E, Yoshimura T. Evaluation of the therapeutic effects and tolerability of modified lenvatinib administration methods for unresectable hepatocellular carcinoma: a preliminary study. Oncol Lett 25: 150, 2023.","DOI":"10.3892\/ol.2023.13736"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Iwamoto H, Suzuki H, Shimose S, et al. Weekends-off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events. Cancers (Basel) 12: 1010, 2020.","DOI":"10.3390\/cancers12041010"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/11\/65_6280-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:29:49Z","timestamp":1780716589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/11\/65_6280-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6280-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"6280-25"}}